Our top pick for
Shattuck Labs, Inc is an other business based in the US. Shattuck Labs shares (STTK) are listed on the NASDAQ and all prices are listed in US Dollars. Shattuck Labs employs 57 staff and has a trailing 12-month revenue of around USD$11.4 million.
|52-week range||USD$17 - USD$60.516|
|50-day moving average||USD$46.1738|
|200-day moving average||USD$37.6607|
|Wall St. target price||USD$54.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$11.4 million|
|Gross profit TTM||USD$-19,331,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 387,585 Shattuck Labs shares held short by investors – that's known as Shattuck Labs's "short interest". This figure is 12.2% up from 345,504 last month.
There are a few different ways that this level of interest in shorting Shattuck Labs shares can be evaluated.
Shattuck Labs's "short interest ratio" (SIR) is the quantity of Shattuck Labs shares currently shorted divided by the average quantity of Shattuck Labs shares traded daily (recently around 108567.22689076). Shattuck Labs's SIR currently stands at 3.57. In other words for every 100,000 Shattuck Labs shares traded daily on the market, roughly 3570 shares are currently held short.
To gain some more context, you can compare Shattuck Labs's short interest ratio against those of similar companies.
However Shattuck Labs's short interest can also be evaluated against the total number of Shattuck Labs shares, or, against the total number of tradable Shattuck Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Shattuck Labs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Shattuck Labs shares in existence, roughly 10 shares are currently held short) or 0.0113% of the tradable shares (for every 100,000 tradable Shattuck Labs shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Shattuck Labs.
Find out more about how you can short Shattuck Labs stock.
We're not expecting Shattuck Labs to pay a dividend over the next 12 months.
You may also wish to consider:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.